CardioPharma Announces Issuance of Global Patent to Mitigate the World’s Top Killer
Press Release May 14, 2024 CardioPharma Inc. (the “Company”), a specialty pharmaceutical company focused on drug development for cardiovascular diseases, announced that on August 29, 2023, the United States Patent and Trademark Office (“USPTO”) issued US Patent 11,737,988 B2 entitled “AntiHypertensive and Cholesterol-Lowering Fixed-Dose Combination and Method of Manufacture.” Additional patents covering the subject matter […]
CardioPharma Targeting Q1 PD Study for Lead Drug Candidate Designed to Improve Compliance and Reduce Cost
WILMINGTON, N.C., December, 2015 – For Immediate Release – CardioPharma, Inc., a pioneer in the development of cardiovascular fixed dose combination products, recently completed its FDA submission batch manufacturing for its lead compound, CP-101, a single capsule combining the gold standards of cardiovascular medicine: an antihypertensive, a cholesterol modifying product and an anti-platelet agent. The company […]
CardioPharma Triple Combination CVD Shows Bio-equivialence
18 November 2013, Toronto, Ontario – Hillcore Life Sciences is pleased to announce that CardioPharma’s lead product, a patented triple-combination once-daily Cardiovascular Disease (CVD) capsule, has successfully completed the FDA required pharmacokinetic study. Acquired in December 2011, Hillcore Life Sciences, through Cardio RX Ventures Canada, owns the exclusive rights to CardioPharma’s lead product in the […]
CardioPharma Closer to NDA for Cardiovascular Disease Polypill
August 28, 2012 – For Immediate Release – CardioPharma, Inc., held a Scientific Advisory Board (SAB) meeting to guide preparations for the filing of the NDA for its lead product, a US manufactured CVD polypill. Also discussed were plans for additional products covered by the Company’s cardiovascular disease platform Intellectual Property. In addition to cardiologists […]
Abacus’ Life Sciences Fund Acquires Cardio RX Ventures Canada
December 23, 2011 – Abacus Private Equity is pleased to announce that through its life sciences fund it has acquired Cardio RX Ventures Canada LLC (“Cardio RX”) from CardioPharma Inc. (“CardioPharma”). Cardio RX owns the exclusive rights to market the CardiaPill in the United States of America, Canada, Australia, New Zealand, South Africa, and Israel. […]